patent

Digital Information For Whom?

요약문: 
On March 4, 2000, the Jinbo Network Center(Korean Progressive Network) has requested that the judgement of the patent on the 'Remote Education via Internet' of Samsung Electronics Co. Limited be invalidated.
Digital Information For Whom?

 

발표일자: 
2001/08/29

Novartis's stubborn Gleevec price means death to patients

요약문: 
Only by this kind of public support was Novartis able to recollect all invested capital within eight months of global marketing of Gleevec. But now, Novartis has twenty years of intellectual property rights.
Novartis's stubborn Gleevec price means death to patients

 

(US $1 => about 1,200 won)

 

발표일자: 
2002/08/01

Patents and Profit: Gleevec Price Talks Break Down.

요약문: 
The National Health Insurance System Board held talks on September 6 to try decide the retail price of Gleevec, a cancer drug used for treating leukemia, only to end by delaying the talks even further. One year has passed since the problem of Gleevec first arose.
Patents and Profit: Gleevec Price Talks Break Down.

 

발표일자: 
2002/11/08

U.S. Influence on Korean Intellectual Property Rights Laws Furthers U.S. Imperialism

요약문: 
The Intellectual Property Right is not merely a possession of copyright holders. Intellectual products would be meaningless if there were no users to enjoy them. It must be recognized that the fundamental aim of the Intellectual Property Right regime is to strengthen the consensus and exchange between the authors and users.

By Joo Chul-min / IPLeft

발표일자: 
2004/02/28

Struggle for Access to Glivec

요약문: 
Struggle for Access to Glivec in South Korea Solidarity Needed Now!!!

Struggle for Access to Glivec
in South Korea
Solidarity Needed Now!!!

Table of Content
- The Beginning: Struggle for Rights of Access to Glivec, Extremely High-Priced Drug
- Excluding Chronic Stage CML Patients out of NHI
- Disapproval of Korean National Health Insurance Price and Temporal Suspension of Glivec Supply in the Market
- What is the problem? Priceless Glivec Kills CML Patients
- What is the problem? Are you asking 30 times of production costs, Novartis?
- What is the problem? Glivec, the Product of Public R&D

발표일자: 
2003/09/25

[Letter] Joint Letter of Korean NGOs to the Indian Embassy in Seoul

요약문: 
On behalf of the 27 Korean NGOs, Trade Unions, I am writing to express our concerns regarding the legal proceedings that Norvatis initiated in India in May 2006, challenging the rejection of its patent application for imatinib mesylate (Gleevec/Glivec) as well as questioning the compliance of the Indian Patents Act with the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights(TRIPS).

Jan 29, 2007

N. Parthasarathi
Ambassador
Indian Embassy in Seoul
37-3, Hannam-Dong Yongsan-ku,
Seoul, South Korea

Re : The Norvatis' legal action in India on the Patent Law

Dear Ambassador N. Parthasarathi

발표일자: 
2007/01/29

[Statement] Are Roche particularly interested in connecting with groups who truly represent patient with HIV/AIDS?

요약문: 
In October 6th, Roche sent a 2nd statement sent to Act Up Paris to explain their policy in Korea. Even though Roche’s goal "is to be transparent"in their communications, Korean activists and people living with HIV/AIDS in Korea can not obtain any clear information from the statement. During the international week of action against Roche, Roche not only refuge to engage in dialogue with activists in Korea and but also make no effort to lower a price of Fuzeon.

South Korean Activists 2nd Refutation on Roche Statement

발표일자: 
2008/10/08

[Statement] Intellectual property rights cannot supersede right to life

소제목: 
Requesting a compulsory license for the production of Fuzeon, an anti-retroviral drug
요약문: 
In 2004, La Roche, a multi-national pharmaceutical corporation, acquired the license to launch Fuzeon, an anti-retroviral product. However, South Korean people with HIV/AIDS have never seen this drug in the last 4 years. This was due to a strong ‘will’ of La Roche requesting the South Korean Government accept the price of 22 million KRW (roughly 22,000 USD) per year. The company has been withholding the distribution of the drug for the last 4 years. The exclusive right of patent protection, owned by La Roche, guarantees that the company’s murderous will is observed in South Korea.

Intellectual property rights cannot supersede right to life
- Requesting a compulsory license for the production of Fuzeon, an anti-retroviral drug

발표일자: 
2008/12/23

[Statement] Korean PLWHA and Civil Society Statement on Roche’s Compassionate Programme of Fuzeon for HIV/AIDS Patients in South Korea

요약문: 
Fuzeon is an essential medicine for HIV/AIDS treatment, but since 2005 Roche has been withholding the distribution of the drug in Korea. We, PLWHA and AIDS activists around the world have been protested against Roche’s murderous policy. However, Roche’s only response was that they would not supply Fuzeon until the South Korean government accepts the unreasonably high price of Fuzeon. To solve this problem, Korea HIV/AIDS Network of Solidarity and Intellectual Property Left requested a compulsory license of Fuzeon in December 2008.

Korean PLWHA and Civil Society Statement on Roche’s Compassionate Programme of Fuzeon for HIV/AIDS Patients in South Korea

발표일자: 
2009/03/04

[기자회견] 생명권을 넘어선 특허권은 존재할 수 없다!

생명권을 넘어선 특허권은 존재할 수 없다!
- 에이즈치료제 푸제온 강제실시 청구


초국적 제약회사 로슈는 지난 2004년 에이즈 치료제 푸제온의 시판허가를 받았다. 그러나 4년이 지난 바로 오늘까지 푸제온은 한국 에이즈 환자들에게는 구경조차 할 수 없는 약이다. 연간 2,200만원을 주지 않으면 절대로 약을 공급하지 않겠다는 로슈의 강력한 ‘의지’ 때문이다. 푸제온 특허에 대한 로슈의 독점적 권한은 로슈의 이러한 ‘살인적 의지’가 한국에서 관철될 수 있도록 보장해 주고 있다.

발표일자: 
2008/12/23